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ABSTRACT
Background: Seasonal allergic rhinitis (SAR) induced by Japanese cedar pollen is a substantial problem in
Japan. Sublingual immuno-therapy (SLIT) is safer than conventional antigen-specific immunotherapy, the only
treatment modality by which complete cure of the disease can be expected. We investigated the safety and effi-
cacy of SLIT in the treatment of cedar pollinosis patients compared to placebo.
Methods: A randomized, placebo-controlled, double-blind study was conducted in 61 cedar pollinosis pa-
tients. Increasing doses of standardized Japanese cedar extract or placebo were administered sublingually in
intervals ranging from daily to once a week after six weeks. The primary efficacy variable was the mean of the
daily total symptom scores (TSS) during the pollen dispersing period. Secondary efficacy variables included the
QOL scores and related variables.
Results: Primary efficacy variable scores were significantly lower for some days in the SLIT group than in the
placebo group (P < .01 or P < .05). Secondary efficacy for the QOL score in SLIT group was almost of half of
placebo group. There was no significant difference in the overall incidence of side effects between the SLIT
group and the placebo group.
Conclusions: SLIT was effective and safe in the treatment of cedar pollinosis.
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INTRODUCTION
In agreement with the results of worldwide epidemi-
ological assessments, the number of patients with al-
lergic rhinitis such as Japanese cedar (JC) pollinosis
in Japan is increasing.1 Okuda considers that the cur-
rent prevalence of allergic rhinitis is 16%, but many
researchers predict that the rate will still increase.2
Pollinosis is a typical type I allergy in which allergic
conjunctivitis and allergic rhinitis develop. In spite of
its refractory nature, pollinosis deteriorates patient
QOL only in severe cases; however, it greatly affects
the patient’s life in general in that they must keep
working even if the condition is severe.3 Many of the
patients with cedar pollinosis have also been sensi-
tized to cypress pollen which disperses after cedar
pollen. Consequently, symptoms of cedar pollinosis
are followed by those of cypress pollinosis; patient
symptoms last, though they are seasonal, for as long
as 4 months (from February to May).
Pharmacological therapy prescribed by general
practitioners is common for the treatment of the dis-
ease. Both oral medications and topical medication,
however, are symptomatic treatment; they do not
cure the disease or remain effective until the follow-
ing year.4 Antigen-specific subcutaneous immuno-
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therapy (SCIT) is the only treatment modality by
which complete cure of the disease can be expected.5
WHO position paper stipulates the use of standard-
ized antigen and the concentration of the antigen to
be maintained.6 The efficacy of the therapy has been
proven in placebo-controlled, double-blind compara-
tive studies using pollen, house dust mite, and animal
protein.6,7 In Japan, it is customary to start the ad-
ministration of causative antigen extract by subcuta-
neous injection at the threshold of skin reaction or its
10-fold diluted concentration, and to increase the
dose gradually.4 Treatment with SCIT requires spe-
cial attention because it may cause, as a side effect,
anaphylactic shock, which prevents the therapy from
becoming popular in Japan.8 In order to reduce the
possibility of this side effect, immunotherapy is ad-
ministered by other routes (sublingual, intranasal,
oral, and transbronchial) in Europe and the United
States, and has achieved desired outcomes.9-11 Espe-
cially, sublingual immunotherapy (SLIT) has become
popular in Europe considerably, and there are many
reports supporting the effectiveness of the therapy.11-
13 As for side effects due to SLIT, there are no reports
of anaphylactic shock, but oral itching, skin reaction
(such as urticaria), and mild asthma-like attacks have
been reported.13 Since cedar pollinosis greatly dete-
riorates patient QOL, many physicians and patients
will opt for immunotherapy if it is proven to be safe.
We conducted a randomized, placebo-controlled
double-blind comparative study to investigate
whether SLIT reported in Europe and the United
States is effective for the treatment of JC pollinosis
and whether it can be performed safely.
STUDY DESIGN
This multi-centre, double-blind, randomized, placebo-
controlled, parallel-group study was conducted in six
centers across Japan between October 2004 and April
2005. The study protocol was approved by the appro-
priate local ethics committees, and the study was con-
ducted in accordance with the Declaration of Helsinki
and Good Clinical Practice guidelines. All patients
provided written informed consent prior to participa-
tion.
SUBJECTS
Patients with JC pollinosis were enrolled in this study
if they had a RAST score of 2 against JC or above and
pollinosis symptoms during the cedar pollen disper-
sal period at least in the past 2 years and if they had
visited any of the following medical institutions: De-
partment of Otorhinolaryngology, Nippon Medical
School; Department of Otorhinolaryngology, Univer-
sity of Fukui; Department of Otorhinolaryngology,
Head and Neck Surgery, Okayama University; De-
partment of Otorhinolaryngology, Dokkyo University
School of Medicine; Department of Otorhinolaryngol-
ogy, University of Yamanashi; and Department of
Otorhinolaryngology, Head and Neck Surgery, Chiba
University. Patients who had nose diseases (peren-
nial allergic rhinitis, nasal septum deviation, or sinusi-
tis) which may interfere with accurate symptom as-
sessment were excluded from the study. Patients re-
ceiving treatment for conditions such as severe car-
diac disease and malignant tumor were also ex-
cluded. As a result, a total of 61 patients were blindly
randomized either to the active group or the placebo
group in the ratio of 2 active to 1 placebo.
METHODS
The study was initiated in October, 2004. Patients
were assigned and randomized to either the active
group or the placebo group. Cedar antigen extract
(active group) at concentrations of 2 to 2000 JAUml
diluted with diluent (made by Torii Pharmaceutical
Co., Ltd.) and diluent alone (placebo group) were
used in eye drop containers (made by Hirakata Plas-
tic).
Administration of the antigen extract was started at
2 JAUml, which is considered a sufficiently safe
level, and was increased to the final maintenance con-
centration of 2000 JAUml. Active drug was adminis-
tered as follows: 1 drop (about 50 μl) to 20 drops
(about 1 ml) of prepared extract was dropped onto
bits of bread (about 1.5 cm × 1.5 cm × 1.5 cm), which
were held sublingually for 2 minutes and then expec-
torated. The treatment schedule was as follows: anti-
gen extract was administered sublingually daily from
Week 1 to Week 4; 20 drops of the antigen extract
2000 JAUml were administered two days per week
in Week 5, once per week in Week 6 and thereafter
throughout the season (Table 1).
Patients experiencing pollinosis symptoms in cedar
and cypress pollen dispersal periods received symp-
tomatic treatment with medications such as antihista-
mines on an as needed basis; such patients were
asked to record the date of treatment in their allergy
diary.
ENDPOINTS
The patients were instructed to fill in their allergy di-
ary from February 22, 2005 to April 6, 2005, the pe-
riod when cedar and cypress pollen dispersed in
2005, and they were also asked to fill in QOL ques-
tionnaire once a month during the same period.
Symptoms recorded in the allergy diary (sneezing,
runny nose, nasal congestion, and interference with
daily life), the total nasal symptom scores calculated
based on each symptom, sneezing, runny nose, nasal
congestion (none; 0, mild; 1, moderate; 2, severe; 3),
and symptom medication scores (antihistamine; 1,
topical steroid; 2, general steroid; 3) were calculated.
The Japanese Allergic Rhinitis QOL Standard Ques-
tionnaire No.1 (JRQLQ No1) was used for the assess-
ment of the QOL of patients with allergic rhinitis
(Fig. 1). Nasal and Ocular symptom scores, QOL-
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Fig. 1 Japanese Alergic Rhinitis QOL Standard Questionnaire No.1 (JRQLQ No1).
II
III  
I
Tick the box that best describes the worst extent to which the symptoms in I 
above have interfered with your quality of life in the past 1―2 weeks. If any of the 
items listed under Quality of life below definitely do not relate to the symptoms in 
I (nose, eyes), then there is no need to tick a box for that particular item. 
Japanese Rhino-conjunctivitis Quality of Life Questionnaire
(JRQLQ No.1)
Nasal and
eye symptoms 
0.
 No  
1.
Mild
2.
Moderate
3.
Severe
4.Very
severe
Quality of life 0. No 1.Yes,slightly
2.Yes,
moder-
ately
3.Yes,
severe
4.Yes,
very
severe 
1. Reduced at work/home
2. Poor moral concentration
3. Reduced thinking power
4. Impaired reading book/newspaper
5. Reduced memory loss
6. Limitation of out of life
    (e.g. sport, picnics) 
Blocked  nose
(nasal congestion)
Runny nose
Itchy nose
Itchy eyes
Watery eyes
7. Limitation going out
8. Hesitation friends or relatives
9. Reduced contact with friends or 
     others by telephone or conversation
10. Not an easy to be around
11. Impaired sleeping
12. Tiredness
13. Fatigue
14. Frustration
15. Irritability
16. Depression
17. Unhappiness
crying
Do not fill out the following
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Patient’s name: Medical record to: Age:    yr Sex: M  F
Name of medical
institution:
Physician’s name: Date:
QOL score: None 0 , Mild 1 , Moderate 2 , Severe 3 , Very severe 4
Total QOL score
Score by QOL category  1―5 points daily life
  8―10 points social 
12―13 points body
  6―7 points out-door
   11 points sleep
14―17 points psyco-life 
Please write the names of drugs used it possible
Score: None: 0 points  Mild: 1 point  Moderate: 2 points  
             Severe: 3 points  Very Severe: 4 points
Sneezing
fine
To patients with allergic rhinitis (including pollinosis)
These days, the aim of medical treatment is not just to cure disease but 
also to give patients a better quality of life. The purpose of this survey is 
to determine to what extent your rhinitis interferes with your life and 
whether it would be improved by treatment. As with all medical treatment, 
the information you provide in this survey will remain strictly confidential.
You may find some of the following questions difficult 
to answer, but  just answer to the best of your ability.
Tick the box that best describes the severity of the worst nasal 
and eye symptoms you have experienced in the past 1―2weeks.
Please circle the number of the face that best describes your general 
state (including your symptoms, life and emotion) in the past 1―2 weeks.   
Diagnosis:
SAR (Antigen) Treatment [prevention,drug,immunology,therapy,operation]
PAR (Antigen) Treatment [prevention,drug,immunology,therapy,operation] 
Non-Allergy: Disease: (     ) Treatment: (     )
0 1 2 3 4
Table 1 Alergen administration schedule (Increasing dosing)
Week 5
(2000 JAU/ml)
Week 4
(2000 JAU/ml)
Week 3
(200 JAU/ml)
Week 2
(20 JAU/ml)
Week 1
(2 JAU/ml)
20 drops1 drop 1 drop 1 drop 1 drop Day 1
2 drops2 drops2 drops2 dropsDay 2
4 drops3 drops3 drops3 dropsDay 3
8 drops4 drops4 drops4 dropsDay 4
20 drops12 drops 6 drops6 drops6 dropsDay 5
18 drops 8 drops8 drops8 dropsDay 6
20 drops 10 drops 10 drops 10 drops Day 7
Initial dose of SLIT for JC polinosis was 1 drop of 2 JAU/ml of standardized JC alergen, and the administrating dose is increased up to 
20 drops of 2000 JAU/ml at 4th week, the maintenance dose.
related questionnaire scores, and the overall face
scale were calculated and statistically analyzed. In
other words, the QOL deterioration score was calcu-
lated by subtracting QOL-related questionnaire
scores recorded in February (i.e. at baseline) from
the scores recorded in the middle of March to April,
when the largest amount of pollen dispersal was ob-
served.
STATISTICAL ANALYSIS
Symptom scores, total symptom scores, and symp-
tom medication scores calculated from the allergy di-
ary in the placebo group and the active group were
analyzed by non-paired t-test and the Chi-squared test
Okubo K et al.
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Fig. 2 The changing the number of cedar and cypress polen dispersals in 2005.
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Table 2 The background of the subjects
p value (＊)Activen＝37
Placebo
n＝22Items
0.90140.65±15.1440.14±15.30Age
Sex
18 (48.6%) 7 (31.8%)Male
19 (51.4%)15 (68.2%)Female
0.1690.43±0.350.62±0.54Nasal and eye symptoms
0.5680.21±0.250.25±0.29QOL-related questionnaire
0.7620.11±0.320.13±0.25Usual daily activities
0.6300.21±0.460.14±0.48Outdoor activities
0.6480.08±0.230.05±0.22Social functioning
0.5370.09±0.290.14±0.36Sleep disturbance
0.5100.24±0.460.17±0.33Physical problems
0.9530.11±0.320.12±0.23Emotional function
0.7801.09±0.741.14±0.73Overal face scale
using SPSS 11.0J. QOL-related questionnaire score of
the 2 groups were compared using analysis of covari-
ance (ANCOVA).
RESULTS
Of the 61 randomized patients, there were 2 dropouts
for those whose treatment was unknown; there were
37 patients in the active group and 22 patients in the
placebo group. In the analysis of allergic symptoms, 2
patients whose outcome was available only in the
form of a diary were excluded, and the results of 36
patients in the active group and 21 patients in the pla-
cebo group were analyzed. In the analysis of QOL, 3
patients were excluded because baseline assessment
was unavailable, and the results of 35 patients in the
active group and 21 patients in the placebo group
were analyzed.
As shown in Table 2, no difference was observed
between the two groups in terms of patient character-
istics (sex was analyzed by the Chi-squared test, and
other items were analyzed by t-test).
In 2005, the number of cedar and cypress pollen
dispersals observed was the largest during the 10-
year period since 1995. According to the data of the
Chiyoda ward―the area nearest to the Nippon Medi-
cal School―announced by the Tokyo Metropolitan
Government, the first pollen dispersal was observed
on February 22, which was about the same time as in
the past years, and an average of 10,625 pollens per
square centimeter by the Durham method were ob-
Sublingual Immunotherapy for Pollinosis
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served during the season (Fig. 2). The number of the
cedar and cypress pollens by the same method ob-
served in each institution was 3424, 2383, 16002, 5859
and 7752 for University of Fukui, Okayama Univer-
sity, Dokkyo University, University of Yamanashi and
Chiba University respectively, and these pollen num-
bers were also largest dispersing during the last ten
years at any place.
Symptom scores for sneezing (Fig. 3A) and runny
nose (Fig. 3B) in the active group were significantly
better than those in the placebo group on 4 days and
2 days, respectively, but no difference was observed
between the active group and the placebo group in
terms of nasal congestion (Fig. 3C). Between the 2
groups, there was no difference in the number of
medications used during the season (Fig. 3D).
The active group had a significantly lower total
symptom score (Fig. 4A) and symptom medication
score (Fig. 4B) on 4 days during the season. Overall,
better outcomes were observed in the active group
during the latter half of the season (i.e. from the end
of March to the beginning of April), which roughly
overlaps the period when the largest amount of cedar
and cypress pollen was dispersed.
In the placebo group, the nasal and ocular symp-
tom score was 1.15, the QOL-related questionnaire
Okubo K et al.
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Fig. 3 The mean changes in each symptom in the season of 2005. A) Mean changes in sneezing. B) Mean changes in runny 
nose. C) Mean changes in nasal congestion. D) Mean changes in medication score. The open square indicates the placebo 
group, the filed square indicates the active group. Significant diference was evaluated as ＊ p ＜0.05; ＊＊ p ＜0.01.
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D)
Placebo Active
Placebo Active
score was 1.10, and the overall face scale score was
1.24; in the active group, the nasal and ocular symp-
tom score was 0.92, the QOL-related questionnaire
score was 0.58, and the overall face scale score was
1.03: the deterioration score in the QOL-related ques-
tionnaire in the active group was only about half the
score in the placebo group (Fig. 5A). In each domain
of QOL question items, deterioration in usual daily
activities, outdoor activities, social functioning, sleep
problems, general physical problems, and emotional
function in the active group was only about half the
score in the placebo group as well. The p-values for
the above domains were 0.089, 0.086, 0.067, 0.060,
0.083 and 0.046; a significant difference was observed
only in emotional function (Fig. 5B).
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Fig. 4 The mean changes in A) the total symptom score (TSS) and B) symptom medication score in the season of 2005. Sig
nificant diference was evaluated as ＊ p ＜0.05; ＊＊ p ＜0.01.
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SIDE EFFECTS
No systemic side effect occurred during SLIT. Local
side effects occurred in six volunteers in the active
group. Mild mouth itching was exhibited in all six vol-
unteers in increasing dose up to 2000 JAU 1 ml, how-
ever this itching was diminished for two or three
times just after allergen administration. All six volun-
teers finished this study totally without any change of
this protocol.
DISCUSSION
Approximately 16% of the Japanese population are af-
fected by Japanese cedar pollinosis2 and the propor-
tion of severe status patients is higher than with
Okubo K et al.
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Fig. 5 The mean changes of A) QOL scores (nasal and eye symptoms, QOL related question
naire, overal face scale) and B) each domain of QOL question items deterioration (in usual daily 
activities, outdoor activities, social functioning, sleep problems, general physical problems, and 
emotional function) from baseline data of February to peak data of peak polen scatering period. 
Diference between placebo and active indicates＊ p ＜0.05 (analysis of covariance, ANCOVA). 
Placebo: n＝21, Active: n＝35.
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grass or ragweed pollinosis, which are the represen-
tative conditions in other countries, and the symp-
toms persist for about 3 months, becoming a social is-
sue. When the amount of pollen increases, patients
show more severe symptoms, and the number of se-
vere status patients is greatest in mid-March (late
season) when the pollen count reaches its peak. Sub-
stantial antigen exposure enhances the antigen-
antibody reaction in the airways (airway hypersensi-
tivity), which is the mechanism involved in severe
pollinosis, and SCIT may control the exacerbation of
the symptoms in the latter half of the cedar pollen
season by inhibiting antigen-related enhancement of
nasal mucosal hypersensitivity.
As shown in the WHO position paper, the effects of
immunotherapy in the treatment of pollinosis have
Sublingual Immunotherapy for Pollinosis
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been substantiated in many double-blind comparative
studies.6 However, the therapy tends to be avoided in
Japan because of factors such as the current high
cost, the complicated procedure involved, and possi-
ble side effects. In Japan, owing to these disadvan-
tages and the fact that the department of allergy has
not been widely established in medical institutions,
pharmacological therapy is the mainstream modality
for the treatment of pollinosis. Still, immunotherapy
is an important modality for the complete cure of al-
lergic diseases.
The efficacy of our SLIT was not demonstrated
based on patient allergy diaries. However, the quality
of life (QOL) score was approximately 12 of that in
the placebo group, with a significant difference. In ad-
dition, a P-value corresponding to a significant differ-
ence was obtained in each QOL domain. In the men-
tal health domain, there was a significant difference.
Assessment using the Japanese guidelines differs
from that in other countries; even a single sneeze is
regarded as (+). In other countries, 4 grades (none,
mild, moderate, and severe) are employed for assess-
ment, and the presence or absence of symptoms is
not evaluated. For this reason, the usefulness of SLIT
may not have been demonstrated based on diaries.
However, the QOL is evaluated via self-assessment,
which is consistent with the system for the self-
reporting of symptoms in other countries (none to se-
vere). Therefore, QOL assessment of SLIT was favor-
able, and was consistent with the reduction rates in
other countries. According to the JRQLQ criteria, the
reduction rate for nasalocular symptoms was 22%,
consistent with the evaluation of SLIT in other coun-
tries. In the future, the JRQLQ criteria, which were
designed in reference to overseas self-assessment,
may be essential for evaluating drug efficacy and
such a novel treatment. This finding is suggestive of
the fact that the QOL questionnaire developed in Ja-
pan is of good quality,14 and that SLIT is effective for
preventing QOL deterioration in patients with pollino-
sis rather than for lowering their symptom score. Pla-
cebo effects of SLIT may be present. However, it was
evaluated in 2005, when the amount of scattered pol-
len was highest over the past 10 years. In addition,
considering that the study involved a placebo-
controlled design, we can conclude that SLIT was ef-
fective for cedar pollinosis in Japan. In evaluating the
treatment response, we cannot rule out the influence
of Japanese cypress pollen scattering. However, in a
study excluding Japanese cypress pollen-positive re-
acting patients, the efficacy of SLIT and reduction
rate for symptoms were also similar (unpublished
data). This maybe caused by the combination of a
large amount of JC and a small amount of cypress
that was dispersed in 2005. These types of pollinosis
should be regarded as JCJapanese cypress pollino-
sis, as their seasons are sequential in the near future.
In addition, a Japanese cypress pollen antigen for im-
munotherapy must be prepared. It should be consid-
ered that symptoms of cedarJapanese cypress polli-
nosis in April are associated with cedar pollen
scattering-related nasal mucosalconjunctival inflam-
mation, not with Japanese cypress pollen scattering
alone.
Less side effects including problematic anaphylaxis
are noted in SLIT although the side effects observed
cannot be theoretically complete anaphylactic shock
when comparing the therapy administered via injec-
tion with sublingual route.15 Similar to the oral al-
lergy syndrome (OAS), which is the focus of public
attention, the development of symptoms such as
strange feelings, oral itching, and swelling were
feared because the antigen remains in the oral cavity;
however, itching was the only reaction observed so
far. The results obtained from the study of tentative
SLIT, which was performed exclusively in the Depart-
ment of Otorhinolaryngology, Nippon Medical
School, were roughly consistent with the results of
similar studies conducted every year thereafter, in-
cluding the results of the study in 2005,16 In our
study of SLIT for the treatment of cedar pollinosis,
symptom medication score was consistently lower
than that of the pharmacological therapy group
throughout the pollen dispersal season. The finding
indicates that patients receiving SLIT tend to use
fewer drugs, which is consistent with the results of a
double-blind comparative study using a placebo,17
SLIT, which is as effective as pharmacological ther-
apy and decreases the amount of drug use, is consid-
ered advantageous also in the current medical econ-
omy in Japan.
The mechanism of action for SLIT, or for conven-
tional SCIT, is still unclear, but for SCIT, reduction of
effector cells18,19 and blocking antibody20-23 have
been the conventional theories. Recently, however, it
has become widely accepted that immunotherapy
may modify the T cell response to natural allergen be-
cause of T cell anergy andor immune deviation.24-27
For SLIT in particular, allergen administered to the
oral mucosa accumulates in the submandibular
lymph node, in which the immune response occurs28
and peaks at approximately 2 hours after administra-
tion.29 In our investigation, an increase in the Stimula-
tory Index in PBMC during the early phase of SLIT
conducted in 1999 shows at least that systemic im-
mune induction was caused by sublingually adminis-
tered antigen.30 In SLIT, it is intended to cause fewer
side effects than SCIT injection by decreasing sys-
temic effects. However, it has become clear that the
therapy also leads to systemic immune induction,
which is greatly different from conventional topical
immunotherapy administered intranasally or orally.
In the present study, SLIT both inhibited the exac-
erbation of symptoms in the latter half of the season
and reduced their severity throughout the season.
Furthermore, there were neither local nor systemic
Okubo K et al.
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side effects, as reported elsewhere for other antigens.
SLIT for cedar pollinosis is a new therapy and in the
future SLIT may by indicated for patients with nasal
allergy caused by other allergens such as house dust
mites or animal dander through improvement of the
administration schedule and establishing the dose at
which the most potent effects are achieved. This
study may contribute to the methodology for the fu-
ture immunotherapy in Japan.
The development of this SLIT in Japan is in pro-
gress as a multi-center study conducted as part of the
research project on the prevention and treatment
of immunological and allergic diseases (H17-
immunology-common-001) entitled “Evaluation re-
search of the relationship between the number of dis-
persed pollen observed by real-time monitoring and
QOL achieved by the current treatment modalities,
and the development of definitive treatment for polli-
nosis”, which is supported by Health and Labour Sci-
ences Research Grants from the Ministry of Health,
Labour and Welfare.
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